Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest narcolepsy Stories

2010-06-08 18:38:42

A small percentage of nurses struggle to remain vigilant during successive 12-hour shifts, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC. Results indicate that lapses of attention among nurses working successive 12-hour shifts ranged from zero to 48 lapses per vigilance test. Although half of nurses committed no more than one lapse, 10 percent...

2010-06-07 13:28:18

Although incident parasomnias are uncommon as children enter adolescence, parasomnias present in preadolescents may persist into the teen years, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC. Results indicate that the rate of persistence after five years was 29 percent for children with bedwetting and 27 percent for children with...

2010-04-27 21:15:00

WORCESTER, Mass., April 27 /PRNewswire-USNewswire/ -- Wake Up Narcolepsy (WUN), a non-profit foundation started in 2008 by Kevin Cosgrove, a 32-year-old with narcolepsy, had 4 runners participating in the April 19, 2010 Boston marathon. The mission of WUN is to promote and foster education and awareness about narcolepsy in order to one day find a cure for this sleep disorder that affects 200,000 people in the United States. Narcolepsy is a chronic neurological disorder caused by the...

2010-04-22 11:37:00

CUMBERLAND, R.I., April 22 /PRNewswire/ -- Sleep HealthCenters, a network of specialized sleep medicine centers and the largest provider of such services in New England, announces the Sleep HealthCenter of Cumberland, Rhode Island has received accreditation by the American Academy of Sleep Medicine (AASM). (Logo: http://www.newscom.com/cgi-bin/prnh/20100317/NE71501LOGO ) AASM accreditation is the gold standard by which the medical community and the public can evaluate sleep medicine...

2010-03-24 08:00:00

BRIGHTON, Mass., March 24 /PRNewswire/ -- Sleep HealthCenters and Gaylord Hospital have entered into a series of agreements regarding sleep medicine services in the state of Connecticut. Sleep HealthCenters will provide management services to existing Gaylord Sleep Medicine sites in Bridgeport, Hartford, Glastonbury, Guilford, North Haven and Trumbull. Gaylord Sleep Medicine is the largest single provider of sleep medicine services in Connecticut. (Logo:...

2010-03-24 07:00:00

SAN DIEGO, March 24, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy. "There is a need for better tolerated, more effective therapies for narcolepsy, especially narcolepsy with cataplexy," said William R. Shanahan, M.D., Arena's Vice President...

2010-02-18 16:00:00

PALO ALTO, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia. Based on a standard 10-month review, the target date for the FDA to complete its review of the NDA under the Prescription Drug User Fee Act (PDUFA) is October 11, 2010. The submission is based on a comprehensive...

2010-02-16 08:48:30

Individuals with the sleep disorder narcolepsy suffer with excessive daytime sleepiness and attacks of muscle paralysis triggered by strong emotions (a condition known as cataplexy). It is thought that narcolepsy is an autoimmune disorder "” that is, it is caused by the individual's immune system attacking certain cells in the body "” but this has not yet been proven definitively. However, Mehdi Tafti and colleagues, at the University of Lausanne, Switzerland, have now identified...

2009-12-15 06:00:00

PALO ALTO, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia. The submission is based on a comprehensive clinical development program for JZP-6, including results from two Phase III clinical trials. In both trials, sodium oxybate significantly decreased pain and fatigue as well as...

2009-11-02 15:30:00

FRAZER, Pa., Nov. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD). NUVIGIL, the longer-lasting isomer of modafinil, is indicated to improve wakefulness in...